Background: Chronic kidney disease (CKD) is a present world health problem. It is widely accepted that uremia, depresses the immunity and make them most susceptible to infection. The relationship between uremia, impaired immune status, and susceptibility to infection has never been established.
Aim: The study was designed to know the association between levels of immunoglobulins and inflammatory marker hs-CRP in various stages of CKD patients and comparing it with healthy controls.
Materials and methods: One hundred twenty-one CKD patients staged based on eGFR were evaluated for serum Immunoglobulins (G, A&M), hs-CRP and compared between the different stages and also with healthy controls (n = 24).
Results: Out of 121CKD patients (male = 88, female = 33) with a mean age of 46 ± 15 years, known cases of hypertension (HTN) were seen in 32%, both DM and HTN 38%, DM only in 1% and remaining were with no h/o DM or HTN. The median levels of blood urea, serum creatinine, and hs-CRP are significantly high across the CKD stages and when compared to healthy controls (p <0.0001). IgM levels showed significant (p = 0.0005) decrease across all the stages of CKD, whereas IgG levels have decreased trend across the stages but statistically not significant.
Conclusion: Based on our findings it can be concluded that a deficiency of immunoglobulins was noticed in a considerable number of uremic patients from all stages of CKD, suggesting inhibition of their synthesis by the uremic state. Uremic patient is associated with a state of immune dysfunction characterized by immunodepression that leads to a high prevalence of infections, and also by immunoactivation causing inflammation (increase in hsCRP).
Johnson DW, Fleming SJ. The use of vaccines in renal failure.ClinPharmacokinet. 1992 Jun; 22(6):434-446.
Kato S, Chmielewski M, Honda H, et al. Aspects of Immune Dysfunction in End-stage Renal Disease. Clinical Journal of the American Society of Nephrology : CJASN. 2008;3(5):1526-1533.
Silverstein DM. Inflammation in chronic kidney disease: role in the progression of renal and cardiovascular disease.Pediatr Nephrol.2009 Aug;24(8):1445-1452.
Chen L, Deng H, Cui H, et al. Inflammatory responses and inflammation-associated diseases in organs. Oncotarget. 2018;9(6):7204-7218.
Dai L, Golembiewska E, Lindholm B, Stenvinkel P.End-Stage Renal Disease, Inflammation and Cardiovascular Outcomes.Contrib Nephrol 2017;191:32-43.
Suliman ME, Stenvinkel P.Contribution of inflammation to vascular disease in chronic kidney disease patients.Saudi J Kidney Dis Transpl.2008 May;19(3):329-345.
Menon V, Greene T, Wang X, Pereira AA, Marcovina SM, et al. C-reactive protein and albumin as predictors of all-cause and cardiovascular mortality in chronic kidney disease. Kidney Int2005;68:766-772.
Koeda Y, Nakamura M, Tanaka F, Onoda T, Itai K, et al. Serum C-reactive protein levels and death and cardiovascular events in mild to moderate chronic kidney disease. Int Heart J 2011; 52:180-184.
Isabel A, Clarke, Douglas J. Ormrodand Thomas E. Miller. Host immune status in uremia. Effect of uremia on resistance to bacterial infection.Kidney International 1983; Vol. 24, pp. 66-73.
Alexiewicz JM, Klinger M, Pirrs TO, Gaciong Z, Linkerisraeli M, Massry SG: Parathyroid hormone inhibits B cell proliferation: Implications in chronic renal failure. J Am SocNephrol 1990;1:236-244.
Katz AL, Hampers CL, Merrill JP: Secondary hyperparathyroidism and renal osteodystrophy in chronic renal failure. Medicine (Baltimore) 1969;48:333-374.
Berson SA, Yalow RS: Parathyroid hormone in plasma in adenomatous hyperparathyroidism, uremia, and bronchogenic carcinoma. Science 1966; 154:907-909.
Massry SG, Coburn JW, Peacock M, Kleeman CR: Turnover of endogenous parathyroid hormone in uremic patients and those undergoing hemodialysis. Trans Am SocArtif Intern Organ 1972;18:416-420.
Gaciong Z, Alexiewicz J, Linker-Israeli M, Shulman I, Pitts T, Massry S. Inhibition of immunoglobulin production by parathyroid hormone, implications in chronic renal failure. Kidney international. 1991;40(1):96-106.
Shin DH, Lim BJ, Han IM, Han SG, Kwon YE, Park KS et al. Glomerular IgG deposition predicts renal outcome in patients with IgA nephropathy. Modern Pathology 2016; 29: 743-752.
Stefan P. Berger AnjaRoos Mohamed R. Daha. Complement and the kidney: What the nephrologist needs to know in 2006? NephrolDial Transplant 2005; 20: 2613-2619.
Panzer SE, Laskowski J, Renner B, et al. IgM exacerbates glomerular disease progression in complement-induced glomerulopathy. Kidney Int. 2015;88(3):528-537.
Eisenberg R. The specificity and polyvalency of binding of a monoclonal rheumatoid factor. Immunochemistry 1976 Apr; 13(4):355-359.
Dissanayake S, Hay FC, Roitt IM. The binding constants of IgM rheumatoid factors and their univalent fragments for native and aggregated human IgG. Immunology. 1977;32(3):309-318.